Jyong Biotech MENS
NASDAQ MENS
$2.05 +0.02 (+0.99%)
At close: Sep 30, 2026 · 4:00 PM EDT

Jyong Biotech (MENS) Construction in Progress (2024 - 2025)

Updated

Jyong Biotech (MENS) posted Construction in Progress of $140,000 for the quarter ended Dec 31, 2025, up 3.7% from $135,000 a year earlier.

Analysis

Jyong Biotech (MENS) Construction in Progress (2024 - 2025) Analysis & Trends

  • In prior years, Jyong Biotech's Construction in Progress was $135,000 in the year ended Dec 31, 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Jyong Biotech 155.86 Mn 155.86 Mn - 140,000.00
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 140,000.00
Dec 31, 2024 135,000.00
API Access

Jyong Biotech Construction in Progress API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=construction-in-progress&ticker=MENS&period=max&api_key=YOUR_API_KEY